Medivir AB (publ) Stock OTC Markets
Equities
MVRBF
SE0020181014
Biotechnology & Medical Research
Sales 2024 * | 32.3M 3.02M 4.12M | Sales 2025 * | 52.05M 4.86M 6.64M | Capitalization | 335M 31.31M 42.72M |
---|---|---|---|---|---|
Net income 2024 * | -75M -7.01M -9.56M | Net income 2025 * | -92M -8.6M -11.73M | EV / Sales 2024 * | 5.27 x |
Net cash position 2024 * | 165M 15.39M 21M | Net cash position 2025 * | 245M 22.9M 31.24M | EV / Sales 2025 * | 1.73 x |
P/E ratio 2024 * |
-5.44
x | P/E ratio 2025 * |
-2.37
x | Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.1% |
Latest transcript on Medivir AB (publ)
Managers | Title | Age | Since |
---|---|---|---|
Jens Lindberg
CEO | Chief Executive Officer | 53 | 22-01-23 |
Director of Finance/CFO | 50 | 19-08-11 | |
Uli Alf Hacksell
CHM | Chairman | 74 | 18-05-02 |
Members of the board | Title | Age | Since |
---|---|---|---|
Uli Alf Hacksell
CHM | Chairman | 74 | 18-05-02 |
Director/Board Member | 68 | 18-05-02 | |
Yilmaz Mahshid
BRD | Director/Board Member | 45 | 20-05-25 |
1st Jan change | Capi. | |
---|---|---|
+8.27% | 115B | |
+12.98% | 107B | |
-13.57% | 22.31B | |
-3.99% | 21.6B | |
-5.79% | 18.23B | |
-39.93% | 17.62B | |
+7.27% | 14.26B | |
+33.66% | 12.37B | |
-28.07% | 8.28B |